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In The Lancet Infectious Diseases, Beth Temple and 
colleagues1 report on a head-to-head comparison 
of the immunogenicity, in a low-income to middle-
income setting (Vietnam), of the currently licenced ten-
valent (PCV10) and 13-valent (PCV13) pneumococcal 
conjugate vaccines. The two vaccines were administered 
in a two-dose primary series (2 months and 4 months 
of age), with a booster dose at 9 months of age 
(a 2 + 1 schedule), with the primary comparison 
of immunogenicity between the vaccines being 
the proportion of recipients with serotype-specific 
antibody concentrations above the recommended 
composite putative threshold of protection developed 
for invasive pneumococcal disease (serotype-specific 
IgG concentration ≥0·35 µg/mL).2 By this measure, 
PCV10 and PCV13 did not differ in immunogenicity. 
This finding was supplemented by assessment of the 
prevalence of functional antibody (opsonophagocytic 
index ≥8) post-vaccination, which was also similar 
between groups. The similarity of PCV10 compared with 
PCV13 in the 2 + 1 dosing schedule was evident after 
both the primary series and the booster dose.
The perceived benefit of PCV13 over that of PCV10 
has been the superior coverage of PCV13 for three 
additional disease-causing serotypes (serotypes 3, 
6A, and 19A). Evidence suggests that PCV13 has no 
effect on serotype 3 invasive pneumococcal disease,3 
whereas evidence of a direct effect on serotypes 6A and 
19A invasive pneumococcal disease in countries using 
PCV10 suggests some cross-protection.4 Similarly 
to past studies, the data in this paper show cross-
reactive IgG and functional antibodies to serotype 
6A and 19A in 61–67% of PCV10 recipients after a 
booster dose; however, these percentages were lower 
than the percentage (>99%) of PCV13 recipients 
in whom functional antibodies to these serotypes 
were induced. Furthermore, the geometric mean 
opsonophagocytic indices were 15–77 times higher 
for serotypes 6A and 19A after the primary series, and 
23–32 times higher after the booster dose in PCV13 
recipients versus PCV10 recipients. The effect of these 
higher titres on direct protection is unclear. The lower 
cross-reactive responses to 19A might explain the 
reported failure of PCV10 to reduce 19A colonisation in 
children and provide indirect protection against 19A in 
unvaccinated individuals.5
Another important observation by Temple and 
colleagues1 was that the immunogenicity of a two-dose 
primary series of PCV13 was similar to a three-dose 
primary series of PCV10 (3 + 0). These data indicate 
the potential for using three doses of PCV13 in a 
2 + 1 schedule rather than a 3 + 0 schedule. This schedule 
could potentially address the waning of protection 
against serotype 1, as reported in African efficacy trials 
of a nine-valent PCV (including serotype 1), which only 
immunised with a three-dose primary series.6
The interpretation of results from this and other similar 
immunogenicity studies, however, have limitations in 
extrapolating to overall direct vaccine effectiveness. 
These limitations include the likelihood of serotype-
specific differences in thresholds of antibody associated 
with protection against invasive pneumococcal 
disease;7 the possibility that concentrations required 
for protection against invasive pneumococcal dis-
ease are not the same as those required for non-
invasive pneumococcal disease syndromes, such as 
non-bacteraemic pneumococcal pneumonia, which 
constitutes the largest burden of severe pneumococcal 
disease;8 and that concentrations of IgG required to 
protect against colonisation might be significantly 
higher than those required to protect against invasive 
pneumococcal disease.9 PCVs protect against the 
acquisition of nasopharyngeal colonisation,10 and 
this protection is key to reducing the transmission of 
pneumococci and, thus, to the indirect protection from 
pneumococcal disease in unvaccinated individuals. A 
pooled analysis, which used seroincidence as a proxy 
of serotype-specific colonisation, suggested that sero-
type-specific antibody concentrations associated with 
reduced odds of nasopharyngeal colonisation range 
from 0·50 μg/mL (62% lower odds of imputed serotype 
6B colonisation) to 2·54 μg/mL (87% reduced odds of 
imputed serotype 19F colonization).11 These estimates 
are approximately 3·1 times higher than the respective 
serotype-specific threshold estimated to confer 
90% reduced risk of invasive pneumococcal disease for 
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sero types 6B (0·16 µg/mL), and 2·2 times higher than 
that for serotype 19F (1·17 µg/mL).7,11
In summary, Temple and colleagues’ study showing 
non-inferiority of PCV10 versus PCV13 in terms of 
immunogenicity against invasive pneumococcal disease 
provides important endorsement of existing WHO 
advice on the use of PCVs for infant immunisation.12 
Furthermore, these data indicate that an individual 
country’s decision on which vaccine to use in a 2 + 1 
schedule to directly protect against vaccine-serotype 
invasive pneumococcal disease might well be influenced 
primarily by the cost of vaccine procurement. The effects 
of the differences between the vaccines in terms of 
absolute antibody concentrations are unclear, but might 
have implications for the effect of vaccines on non-
invasive disease, carriage, and indirect protection for at 
least some serotypes. However, these questions require 
further study.
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Control of scabies and secondary impetigo: optimising 
treatment effectiveness in endemic settings
Scabies is more than a common parasitic skin 
disease1 and health authorities in low-income and 
middle-income countries now recognise it as a public 
health issue. In 2017, WHO added scabies to the 
list of neglected tropical diseases for the following 
reasons: it is very common (point prevalence of up 
to 200 million),2 has a substantial global burden 
in disability-adjusted life-years,3,4 has notable 
psychosocial and economic effects caused by stigma 
and work disruption, and the major sleep disturbances 
and damage to the skin barrier caused by scratching. 
Sarcoptes scabiei also inhibits complement pathways, 
leading to streptococcal and staphyloccocal super-
infection of the skin.5
Controlling secondary bacterial pyodermas caused 
by scabies is crucial. Patients in tropical areas with 
Staphylococcus aureus bacteraemia and scabies have a 
higher mortality than those without scabies;6 but other 
life threatening infections such as cellulitis or necrotising 
soft tissue infection might occur, and impetigo might lead 
to haematuria or post-streptococcal glomerulonephritis 
and acute rheumatic fever or rheumatic heart disease.7,8
In The Lancet Infectious Diseases, Lucia Romani 
and colleagues9 report on the efficacy of the 
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For WHO list of neglected 
tropical diseases see http://www.
who.int/neglected_diseases/
diseases/en/
